Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro.

PubWeight™: 1.49‹?› | Rank: Top 4%

🔗 View Article (PMID 8045498)

Published in Hepatology on August 01, 1994


K Matsumoto1, H Fujii, G Michalopoulos, J J Fung, A J Demetris

Author Affiliations

1: Pittsburgh Transplant Institute, Department of Pathology, University of Pittsburgh, Pennsylvania 15213.

Articles citing this

Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol (2005) 1.69

Liver regeneration: alternative epithelial pathways. Int J Biochem Cell Biol (2009) 1.55

Foxa1 and Foxa2 regulate bile duct development in mice. J Clin Invest (2009) 1.43

ATP-binding cassette sterol transporters are differentially expressed in normal and diseased human gallbladder. Dig Dis Sci (2012) 1.42

Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg (1998) 1.32

The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol (2000) 1.31

Characterization and isolation of ductular cells coexpressing neural cell adhesion molecule and Bcl-2 from primary cholangiopathies and ductal plate malformations. Am J Pathol (2000) 1.11

Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut (2001) 1.10

Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sci (2005) 1.02

Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis. Hepatology (2010) 1.01

High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut (2002) 1.01

Advances in cholangiocyte immunobiology. Am J Physiol Gastrointest Liver Physiol (2012) 0.96

Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease. World J Gastroenterol (2006) 0.94

Expression of cytokine and chemokine mRNA and secretion of tumor necrosis factor-alpha by gallbladder epithelial cells: response to bacterial lipopolysaccharides. BMC Gastroenterol (2002) 0.93

Hepatocyte growth factor and c-Met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis. Am J Pathol (2002) 0.90

Growth factor- and cytokine-driven pathways governing liver stemness and differentiation. World J Gastroenterol (2010) 0.88

Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults. Am J Physiol Gastrointest Liver Physiol (2010) 0.88

Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth. World J Gastroenterol (2006) 0.86

NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia. Am J Pathol (1997) 0.83

Cholangiopathy with respect to biliary innate immunity. Int J Hepatol (2011) 0.83

Inhibition of notch signaling pathway prevents cholestatic liver fibrosis by decreasing the differentiation of hepatic progenitor cells into cholangiocytes. Lab Invest (2015) 0.82

Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. Dig Liver Dis (2008) 0.82

Foxa1 and Foxa2 regulate bile duct development in mice. J Hepatol (2010) 0.81

Ductal plates in hepatic ductular reactions. Hypothesis and implications. II. Ontogenic liver growth in childhood. Virchows Arch (2011) 0.81

Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia. Haemophilia (2010) 0.81

Requirement for TNF-Tnfrsf1 signalling for sclerosing cholangitis in mice chronically infected by Cryptosporidium parvum. Clin Exp Immunol (2002) 0.79

Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc (2016) 0.78

Daily serum interleukin-6 monitoring in multiple organ transplantation with or without liver allografts. Transplant Proc (1996) 0.78

Uptake of bacterial lipopolysaccharide and expression of tumor necrosis factor-α-mRNA in isolated rat intrahepatic bile duct epithelial cells. World J Gastroenterol (1997) 0.77

Apamin suppresses biliary fibrosis and activation of hepatic stellate cells. Int J Mol Med (2017) 0.75

Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget (2016) 0.75

Biliary epithelial apoptosis, autophagy, and senescence in primary biliary cirrhosis. Hepat Res Treat (2010) 0.75

Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget (2017) 0.75

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Liver transplantation (1). N Engl J Med (1989) 4.53

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Primary culture of parenchymal liver cells on collagen membranes. Morphological and biochemical observations. Exp Cell Res (1975) 3.87

Left-right asymmetric expression of the TGF beta-family member lefty in mouse embryos. Nature (1996) 3.79

Cloning and structure of a yeast gene encoding a general transcription initiation factor TFIID that binds to the TATA box. Nature (1989) 3.74

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98

Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97

Liver transplantation (2). N Engl J Med (1989) 2.93

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science (1994) 2.65

A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res (1989) 2.59

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci U S A (1991) 2.55

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48

A novel B cell-derived coactivator potentiates the activation of immunoglobulin promoters by octamer-binding transcription factors. Cell (1992) 2.43

cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol (1996) 2.42

Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res (2001) 2.41

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

Tumor necrosis factor-alpha (TNF-alpha) plays a protective role in acute viralmyocarditis in mice: A study using mice lacking TNF-alpha. Circulation (2001) 2.36

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24

Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22

Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20

Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20

Control of hepatocyte replication by two serum factors. Cancer Res (1984) 2.20

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19

Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17

Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation (1986) 2.17

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16

Acute Wernicke's encephalopathy: comparison of magnetic resonance images and autopsy findings. Intern Med (1996) 2.14

Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12

The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev (1995) 2.11

Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol (1990) 2.11